Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725078 | 0.91 | MAP3K11 (0.50) | KMT2AMEN1GAKBRD4CYP3A4 | |
| SCHEMBL723277 | 0.91 | MAP3K11 (0.50) | KMT2AMEN1GAKSYKCYP3A4 | |
| SCHEMBL21951883 | 0.87 | KMT2A (0.53) | KMT2AMEN1GAKSYKBRD4 | |
| SCHEMBL12224207 | 0.85 | MEN1 (0.57) | KMT2AMEN1BRD4 | |
| SCHEMBL723823 | 0.84 | MAP3K11 (0.59) | KMT2AMEN1GAKBRD4 | |
| SCHEMBL723813 | 0.84 | GAK (0.49) | GAKSYKBRD4CDK2KIT | |
| SCHEMBL28525140 | 0.84 | SYK (0.52) | KMT2AMEN1GAKSYKBRD4 | |
| SCHEMBL17732363 | 0.83 | MEN1 (0.43) | KMT2AMEN1GAKBRD4TTK | |
| SCHEMBL804651 | 0.81 | TUBB4A (0.47) | KMT2AMEN1KDM4EMAPTHPGD | |
| SCHEMBL21951887 | 0.80 | MEN1 (0.59) | KMT2AMEN1SYKBRD4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | claimed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | claimed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | claimed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3793548-A1 | COMPOUNDS FOR TREATMENT OF PANCREATIC CANCER | University of Tennessee Research Foundation (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3793549-A1 | COMPOUNDS FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND OVARIAN CANCER | University of Tennessee Research Foundation (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9447049-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-09-20 | — | — | US | disclosed |
| EP-3064204-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx, Inc. (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9334242-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2542081-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | KMT2A 2242/4885MEN1 165/4885GAK 256/4885 |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | KMT2A 2242/4885MEN1 165/4885GAK 256/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | KMT2A 2242/4885MEN1 165/4885GAK 256/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | KMT2A 2242/4885MEN1 165/4885GAK 256/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | KMT2A 2242/4885MEN1 165/4885GAK 256/4885 |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | KMT2A 2242/4885MEN1 165/4885GAK 256/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | KMT2A 2242/4885MEN1 165/4885GAK 256/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | KMT2A 2242/4885MEN1 165/4885GAK 256/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | KMT2A 2242/4885MEN1 165/4885GAK 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.